Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 5/20 | 0.69 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.69 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 4/20 | 0.52 |
| ▸ | MET | P08581 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896856 | 1.00 | SRC (0.69) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3890976 | 0.90 | SRC (0.74) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3901875 | 0.84 | SRC (0.79) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3891073 | 0.82 | HDAC8 (0.55) | HDAC1HDAC8 | |
| SCHEMBL3892218 | 0.82 | HDAC8 (0.55) | HDAC1HDAC8 | |
| SCHEMBL3895814 | 0.82 | SRC (0.76) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3895310 | 0.82 | SRC (0.82) | SRCTGFBR1PDGFRAKDRAXL | |
| SCHEMBL3894144 | 0.82 | SRC (1.00) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3896201 | 0.80 | SRC (0.66) | SRCTGFBR1PDGFRAKDRMET | |
| SCHEMBL3905198 | 0.80 | SRC (0.76) | SRCTGFBR1PDGFRAKDRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-12-17 | — | — | US | disclosed |
| US-7560558-B2 | Compound having TGFβ inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1548008-A1 | COMPOUND HAVING TGF-BETA INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111375-A1 | Compound having tgfß inhibitory activity and medicinal composition containing the same | TGFB1, TGFBR1, TGFBR2 | SRC 399/4885TGFBR1 2/4885PDGFRA 36/4885 |
| US-20090312313-A1 | COMPOUND HAVING TGFBETA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TGFB1, TGFBR1, TGFBR2 | SRC 496/4885TGFBR1 2/4885PDGFRA 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.